PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31901955-3	2020	Furthermore, CUDC-907 is an oral inhibitor of class I phosphoinositide 3-kinase (PI3K) as well as class I and II histone deacetylase (HDAC) enzymes.	CUDC-907	13-21	histone deacetylase 9	Homo sapiens	113-132	
31901955-3	2020	Furthermore, CUDC-907 is an oral inhibitor of class I phosphoinositide 3-kinase (PI3K) as well as class I and II histone deacetylase (HDAC) enzymes.	CUDC-907	13-21	histone deacetylase 9	Homo sapiens	134-138	
31901955-4	2020	METHODS: In this study, we evaluated the effect of combination therapy of CUDC-907 and ABL TKIs, using BCR-ABL-positive cell lines and primary samples.	CUDC-907	74-82	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	103-110	
31901955-10	2020	CONCLUSION: Taken together, our results indicate that administration of CUDC-907, a dual PI3K and HDAC inhibitor, may be an effective strategy against ABL TKI-resistant cells, including cells harboring the T315I mutation.	CUDC-907	72-80	histone deacetylase 9	Homo sapiens	98-102	
31901955-10	2020	CONCLUSION: Taken together, our results indicate that administration of CUDC-907, a dual PI3K and HDAC inhibitor, may be an effective strategy against ABL TKI-resistant cells, including cells harboring the T315I mutation.	CUDC-907	72-80	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	151-154	
31901955-11	2020	Moreover, CUDC-907 may enhance the cytotoxic effects of ABL TKI when a combined treatment strategy is used against Philadelphia chromosome-positive leukemia cells.	CUDC-907	10-18	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	56-59